Alongside operational BRIDGE-building, Evotec is strategically considering challenges and best practices in transitioning from academic drug discovery to an investable proof of concept. Explore these strategic insights in our comprehensive White Paper series: ‘From academic concept to commercial reality: How to accelerate translational drug discovery’, where we openly share perspectives to stimulate dialogue among academic researchers, investors, and industry professionals. After presenting the Introduction, Chapter 1, and Chapter 2, today we introduce Chapter 3, titled 'Just Short of a Decathlon: A Day in the Life of a BRIDGE Expert in Residence' which concludes the series. You can download and read all chapters from our Science Pool - https://hubs.ly/Q02J4vnt0 #researchneverstops
About us
A BRIDGE (Biomedical Research, Innovation & Development Generation Efficiency) is an integrated fund and award framework to accelerate the translation of early-stage drug discovery from academia to pharma. The goal of our BRIDGE pre-seed partnerships is to unlock the potential of academic innovation from therapeutic concept to investable data point by making our know-how in drug discovery, our technology platforms and matched funding readily available to academic researchers.
- Website
-
www.evotec.com
External link for Evotec BRIDGEs
- Industry
- Pharmaceutical Manufacturing
- Company size
- 5,001-10,000 employees
Updates
-
With a day packed full of exciting talks, the first joint Science Day of beLAB2122 and beLAB1407 brought together academics from across Germany and the UK to discuss progress with funded projects and share learnings. Covering everything from ASOs to novel protein degradation platforms, it was extremely rewarding for all to be submerged in terrific science and see how the Evotec Academic BRIDGEs model is accelerating novel science with our academic collaborators. Learn more about beLAB and the Academic BRIDGEs by visiting the website - https://hubs.ly/Q02z2WJG0 #ResearchNeverStops #Evotec #TogetherForMedicinesThatMatter
-
-
A unique differentiator of Evotec's BRIDGEs model is the role of the Expert In Residence (EIR). Today we are pleased to share more insights on this role through an interview with Antonio Felici, VP Academic Partnerships at Evotec and EIR of EXTEND, our BRIDGE partnership with CDP Venture Capital SGR, Angelini Ventures and a cohort of Italian research institutions. Learn more about EXTEND and Evotec’s Academic BRIDGEs by visiting the website - https://hubs.ly/Q02F2Xfw0
Meet the Team: Antonio Felici, Expert In Residence The Expert in Residence (EIR) is the link between academic partners and investors. The EIR is accountable for identifying new drug discovery opportunities,new academic and corporate partners, creating workplans and providing guidance throughout the whole process aimed at launching new startups. We are glad to introduce you to Antonio Felici, EIR of EXTEND and the main contact since the beginning of your journey with us. Learn more about EXTEND by visiting the website: https://extend-tt.vc/ What is your background? I spent over 25 years in Drug Discovery and Development in Verona with GlaxoWelcome, GlaxoSmithKline,Aptuit and Evotec where I cover of role of Vice President in the Academic Partnerships Department. I am Advisory Board Member of AUROBAC Therapeutics What does your role involve? The EIR role is central to manage the interactions among the main players of the initiative, such as Research Institutes, TTOs, PIs, EXTEND Board of Directors, Scientific Advisory Board,Project Teams and Entrepreneur in Residence. This with the main objective to select innovative drug discovery projects with the highest probability to deliver novel treatments in therapeutic areas with high unmet medical need. What qualities are essential to fulfil your role? This role is a compendium of capabilities to effectively support and interact with a multidisciplinary environment EXTEND relies, including scientific background, deep experience in commercial drug discovery and development, project & portfolio management,strong communication and organizational skills. What is the most exciting aspect of your job? Discussing science and potential development of a project is what excites me at most. I find very constructive and rewarding the mutual exchange of experiences and ideas with highly qualified scientists as well as the challenges of translating groundbreaking research projects into novel and effective therapeutic approaches. What is the main challenge you face in your job and how do you handle it? Such a complex environment brings several challenges and thanks to the internal support from EXTEND and my Team I can effectively manage them, such as the need to address different expectations. Indeed, a research team may need guidance to mitigate the risks associated with the project by providing specific data,while the "venture" would need proof for industrialization and finding the right balance is needed. How do you implement effective leadership? This is a very difficult question as I do not think I work specifically for that. I believe trust, respect, honesty, fairness,support and care when providing feedback to the partners are instrumental for an effective and successful interaction. What is your favorite quote? I find the quote from Margherita Hack “In life there is nothing to fear,only to understand” perfectly in line with what is needed to discover and develop novel therapies to cure patients worldwide.
-
-
-
-
-
3
-
-
Thomas Hanke, EVP and Head of Academic Partnerships shares his expertise in accelerating translation of academic research into commercially viable products in an insightful keynote at the "From Lab to Launch" event hosted by the Start-up Lab Bahrenfeld. Learn more about the event and Thomas' keynote in the full article here- https://hubs.ly/Q02FNJPT0 #ResearchNeverStops #Evotec #TogetherForMedicinesThatMatter
-
-
The participation of Stephen Hess, Expert-in-Residence of 65LAB BRIDGE, in the first Mid-Year Mixer organized by ClavystBio Node 1 was highly appreciated. Never underestimate the value of good food when joining such a great community! Keep following us and learn more about Academic BRIDGEs by visiting the website - https://hubs.ly/Q02DRgxm0
Last week, we hosted our first Mid-Year Mixer with our ClavystBio Node 1 community. Everyone was encouraged to bring a friend and join in on the fun! It was fantastic to meet, mingle, catch up and have great conversations over hotdogs, beers, and chips. 🍻🌭 A special shoutout to Stephen Hess, #65LAB Expert in Residence, for whipping up an incredible Jalapeno and bacon relish... 🌶️🥓 Stay tuned to our LinkedIn page for more exciting events at our collaboration space, #Node1! #clavystcommunity #collaboratetoinnovate
-
-
-
-
-
2
-
-
On July 4, beLAB2122 and beLAB1407, two of Evotec´s prolific Academic BRIDGEs are bringing together the respective academic communities for the first time in a joint Science Day. This unique event in Heidelberg offers our University partners to share their findings, discovery synergies and accelerate the development of a growing portfolio. We are looking forward to some interesting talks and hearing about the progress. Learn more about beLAB and the Academic BRIDGEs by visiting the website: https://hubs.ly/Q02F2Xfw0
-
-
Are there great ideas for novel human therapeutics within the halls of this innocuously-named edifice? Researchers in the Wet Science Building at the National University of Singapore are working on improved chemotherapies for solid tumor cancers. Keep following us and learn more about Academic BRIDGEs by visiting the website - https://hubs.ly/Q02DRgxm0
-
-
Tubulis announced today that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation to its lead antibody-drug conjugate (ADC) TUB-040 for the treatment of patients with platinum-resistant ovarian cancer. TUB-040 is a next-generation NaPi2b-targeting Exatecan ADC based on Tubulis’ proprietary P5 technology with superior biophysical properties that demonstrated effective and durable responses in a range of preclinical models, including ovarian cancer. The candidate is currently being evaluated in a multicenter Phase I/IIa study (NAPISTAR 1-01, NCT06303505) in patients with platinum-resistant high-grade ovarian cancer (PROC) or relapsed/refractory adenocarcinoma non-small cell lung cancer (NSCLC), who have exhausted other available treatment options. To learn more, read the press release here-https://hubs.ly/Q02DH3B70 #ResearchNeverStops #TogetherForMedicinesThatMatter
-
-
Evotec announced that the University of Bristol has been granted an award within the framework of the beLAB1407 BRIDGE partnership to develop a novel antisense oligonucleotide (“ASO”) based treatment for atherosclerosis, the leading cause of cardiovascular diseases. To learn more, read the full press release here- https://hubs.ly/Q02DzLl30 #ResearchNeverStops #TogetherForMedicinesThatMatter
-
-
Evotec works with a wide range of Small/Medium Enterprises (SMEs) supporting drug discovery and development, and our BRIDGEs catalyze the creation of new #spinout SMEs from our academic partners – indeed they are the life blood of the #lifescience sector. "It was a pleasure to contribute today to NCUB’s panel analyzing their excellent report on the apparent decline in SME-University interactions, the putative causes and recommendations to reverse this trend. Much can be ascribed to the general macroeconomic challenges associated with the pandemic and subsequent inflationary environment, but stability of funding sources to replace ESIF/ERDF funding is a must for our next government. Thanks to Prof Graeme Reid for moderating and to excellent co-panelists Rosalind Gill and Paul Noon." - Adam Stoten, SVP Academic Partnerships.
-